New pyrrolidinoꢀ and pyrrolinofullerenes
Russ.Chem.Bull., Int.Ed., Vol. 57, No. 5, May, 2008
909
solution of fullerene. Then the corresponding aldehyde (5—10 equiv.)
was added to the reaction mixture. In some cases, a solution of
imine (1.2 equiv.), which was prepared by the reaction of
equimolar amounts of picolylamine and aldehyde in CH2Cl2 in
the presence of anhydrous sodium sulfate,29 was added to
fullerene. The reaction mixture was heated in air or under argon
for 2—10 min (if a 2ꢀpicolylamine derivative was used as the
reactant) or 10—30 min (if the reactant contained no 2ꢀpicolyl
groups). The progress of the reaction was monitored by TLC.
After completion of the reaction, the reaction mixture was cooled
to room temperature, diluted with toluene (100 mL; in the case
of compound 17, the reaction mixture was additionally diluted
with hexane (450 mL)), and chromatographed on a silica gel
column (40—60 µ). Unconsumed fullerene was eluted with toluꢀ
ene (or with a 1 : 2 toluene—hexane mixture in the case of 17);
subsequent elution was carried out with a toluene—methanol
mixture (a toluene—hexane mixture for compound 17). After
chromatography, the solutions of pyrrolidinofullerenes were
concentrated on a rotary evaporator to 3—5 mL, and hexane
(20—30 mL) was added. The precipitates that formed were sepaꢀ
rated by centrifugation, washed three times with hexane, and
dried in air. The spectroscopic data for compounds 9—12, 17,
and 24—27 have been published earlier;37 for compounds 28—30,
see Ref. 44.
139.94; 141.38; 141.44; 141.59; 141.72; 141.85; 141.97; 142.15;
142.26; 142.39; 142.49; 142.83; 142.98; 144.19; 144.30; 144.38;
144.49; 144.86; 144.89; 144.92; 144.96; 145.08; 145.10; 145.18;
145.32; 145.37; 145.42; 145.52; 145.68; 145.70; 145.89; 145.98;
146.01; 146.10; 146.58; 146.61; 147.04; 147.13; 149.09; 149.40;
149.80; 150.07; 152.40; 153.27; 153.57; 156.83; 158.45; 159.90.
Compound 18. 1H NMR (400 MHz, CDCl3), δ: 3.75 and
4.33 (both d, 1 H each, CH2, J = 14.3 Hz); 5.96 (s, 1 H); 7.21 (d,
1 H, CHpy, J = 7.8 Hz); 7.38 (dt, 1 H, CHpy, J = 5.6 Hz, J = 1.8 Hz);
7.40 (s, 1 H); 7.45 (dd, 1 H, CHpy, J = 7.2 Hz, J = 4.1 Hz); 7.73
(t, 1 H, CHpy, J = 8.4 Hz, J = 1.6 Hz); 7.95 (br.s, 1 H, CHpy);
7.97 (d, 2 H, CHpy, J = 7.8 Hz); 8.66 (d, 1 H, CHpy, J = 3.4 Hz);
8.69 (s, 1 H, CHpy); 8.72 (d, 2 H, CHpy, J = 5.0 Hz); 9.06 (d,
1 H, CHpy, J = 4.7 Hz). 13C NMR (100 MHz, CS2—C6D12), δ:
48.44 (CH2); 72.93; 74.57; 74.71; 75.63; 122.51; 123.11; 123.65;
125.13; 125.35; 125.51; 128.00; 128.71; 130.78; 132.51; 132.77;
134.80; 135.17; 135.89; 136.18; 137.26; 137.81; 139.22; 139.28;
139.73; 139.88; 141.25; 141.29; 141.33; 141.50; 141.57; 141.62;
141.68; 141.72; 141.82; 142.01; 142.15; 142.29; 142.38; 142.70;
142.88; 144.05; 144.15; 144.25; 144.35; 144.76; 144.81; 144.88;
144.96; 145.00; 145.23; 145.29; 145.41; 145.60; 145.64; 145.79;
145.86; 145.97; 146.05; 146.12; 146.18; 146.33; 146.47; 147.11;
147.21; 148.89; 149.11; 149.86; 150.01; 150.26; 152.11; 153.13;
153.29; 156.62; 159.91.
Compound 13. 1H NMR (400 MHz, CS2—acetoneꢀd6), δ:
4.34 (br.s, 1 H, NH); 6.44 and 6.97 (both s, 1 H each, CH—
NH); 7.36 (m, 2 H, CHpy, CHPh); 7.46 (t, 2 H, CHPh, J = 8.3
Compound 19. 1H NMR (600 MHz, CS2—acetoneꢀd6), δ:
3.70 and 4.30 (both d, 1 H each, CH2, J = 14.0 Hz); 5.95 (s, 1 H,
CH—N); 7.17 (t, 1 H, CH, J = 7.8 Hz); 7.25 (d, 1 H, CHpy
J = 7.8 Hz); 7.38 (m, 2 H, CHpy); 7.45 (s, 1 H, CH—N); 7.81
(dt, 1 H, CHpy, J = 7.8 Hz, J = 1.8 Hz); 7.99 (d, 1 H, CHpy
,
Hz); 7.56 (d, 1 H, CHpy, J = 7.6 Hz); 7.82 (dt, 1 H, CHpy
,
J = 7.6 Hz, J = 1.6 Hz); 7.95 (d, 2 H, CHPh, J = 7.6 Hz); 8.85
(d, 1 H, CHpy, J = 4.4 Hz).
,
J = 7.3 Hz); 8.31 (br.s, 1 H, CHpy); 8.48 (s, 1 H, CHpy); 8.56
(m, 2 H, CHpy); 9.09 (d, 1 H, CHpy, J = 4.6 Hz); 9.12 (br.s, 1 H,
CHpy). 13C NMR (150 MHz, CS2—acetoneꢀd6), δ: 48.77 (CH2);
73.29; 74.73; 74.87; 75.64; 123.07; 123.65; 125.87; 128.43;
129.15; 133.40; 135.43; 136.74; 137.73; 138.34; 139.63; 140.21;
141.67; 141.70; 141.77; 141.88; 142.03; 142.06; 142.09; 142.16;
142.23; 142.47; 142.53; 142.64; 142.65; 142.69; 142.76; 143.10;
143.25; 144.48; 144.58; 144.68; 144.74; 145.13; 145.20; 145.23;
145.24; 145.38; 145.45; 145.47; 145.61; 145.65; 145.74; 145.90;
145.96; 145.98; 146.02; 146.04; 146.16; 146.19; 146.25; 146.33;
146.39; 146.68; 147.35; 147.43; 149.10; 149.96; 150.00; 150.18;
150.20; 151.16; 152.57; 153.67; 153.89; 157.19; 160.05; 169.16.
Compound 20. 1H NMR (600 MHz, CDCl3), δ: 3.80 and
4.39 (both d, 1 H each, CH2, J = 14.2 Hz); 6.80 (br.s, 2 H,
CH—N); 7.31 (dt, 2 H, CHpy, J = 5.1 Hz, J = 3.2 Hz); 7.45 (dd,
1 H, CH, J = 4.6 Hz, J = 3.2 Hz); 7.72 (br.s, 2 H, CHpy); 7.77
(t, 2 H, CHpy, J = 7.3 Hz); 8.00 (d, 1 H, CHpy, J = 7.3 Hz); 8.66
(d, 1 H, CHpy, J = 4.6 Hz); 8.75 (s, 1 H, CHpy); 8.88 (br.s, 2 H,
CHpy). 13C NMR (150 MHz, CS2—acetoneꢀd6), δ: 48.85 (CH2);
74.28; 76.42; 122.94; 123.57; 124.73; 133.73; 135.53; 136.39;
136.58; 137.41; 139.50; 139.95; 141.56; 141.83; 141.92; 142.09;
142.17; 142.29; 142.55; 142.65; 143.13; 144.58; 144.63; 145.14;
145.16; 145.25; 145.54; 145.67; 145.96; 146.00; 146.05; 146.22;
146.26; 146.56; 147.33; 148.98; 149.91; 150.03; 153.65; 156.01;
159.31.
Compound 14. 1H NMR (400 MHz, CS2—acetoneꢀd6), δ:
4.13 (t, 1 H, NH, J = 7.3 Hz); 6.13 and 6.21 (both d, 1 H each,
CH—NH, J = 7.3 Hz); 7.17 (d, 1 H, CH of imidazole, J = 16.3
Hz); 7.30 (d, 1 H, CH of imidazole, J = 12.8 Hz); 7.33 (dt, 1 H,
CHpy, J = 7.6 Hz, J = 2.5 Hz); 7.54 (d, 2 H, CHAr, J = 8.5 Hz);
7.86 (dt, 1 H, CHpy, J = 7.6 Hz, J = 1.6 Hz); 7.87 (s, 1 H, CH of
imidazole); 8.10 (d, 1 H, CHpy, J = 6.6 Hz); 8.12 (d, 2 H, CHAr
,
J = 8.4 Hz); 8.72 (d, 1 H, CHpy, J = 4.3 Hz) (assignment was
1
confirmed by H—1H NOESY).
Compound 15. 1H NMR (400 MHz, CDCl3), δ: 4.00 and
4.46 (both d, 1 H each, CH2, J = 15.4 Hz); 6.91 (br.s, 2 H,
CH—N); 7.20 (t, 1 H, CHpy, J = 7.5 Hz); 7.28 (t, 2 H, CHpy
,
J = 7.5 Hz); 7.72 (br.s, 4 H, CHpy); 7.90 (t, 1 H, CHpy, J = 7.5 Hz);
8.10 (d, 1 H, CHpy, J = 7.8 Hz); 8.62 (d, 1 H, CHpy, J = 3.7 Hz);
8.85 (d, 2 H, CHpy, J = 4.1 Hz). 13C NMR (100 MHz,
CS2—C6D12), δ: 52.56 (CH2); 74.10; 76.23; 121.80; 122.06;
122.40; 124.65; 125.30; 128.16; 128.86; 130.98; 135.79; 135.99; 136.46;
137.29; 139.26; 139.76; 141.31; 141.60; 141.68; 141.86; 141.94;
142.07; 142.32; 142.42; 142.90; 144.36; 144.40; 144.92; 145.00;
145.30; 145.44; 145.73; 145.77; 145.86; 145.98; 146.03; 146.41;
146.83; 147.08; 149.34; 153.60; 155.89; 158.96; 159.32. ESI MS
(MeOH + HCOOH), m/z (Irel (%)): 1027 [M•H3O]+ (100).
Compound 16. 1H NMR (400 MHz, CDCl3), δ: 3.96 and
4.40 (both d, 1 H each, CH2, J = 15.2 Hz); 6.12 (s, 1 H,
CH—N); 7.31 (m, 2 H, CHpy); 7.43 (s, 1 H, CH—N); 7.70 (t,
1 H, CHpy, J = 7.5 Hz); 7.92 (m, 4 H, CHpy); 8.07 (d, 1 H,
CHpy, J = 7.8 Hz); 8.61 (d, 1 H, CHpy, J = 4.1 Hz); 8.67 (m,
2 H, CHpy); 9.01 (d, 1 H, CHpy, J = 4.1 Hz). 13C NMR
(100 MHz, CS2—C6D12), δ: 52.44 (CH2); 73.31; 74.82; 75.71;
76.20; 121.85; 121.91; 122.48; 123.89; 125.97; 128.11; 130.92;
135.40; 136.00; 136.08; 137.62; 138.17; 139.27; 139.38; 139.83;
Compound 21. 1H NMR (600 MHz, CS2—acetoneꢀd6), δ:
3.62 and 4.30 (both d, 1 H each, CH2, J = 14.0 Hz); 5.86 (s, 1 H,
CH—N); 7.02 (d, 2 H, CHAr, J = 7.2 Hz); 7.09 (d, 1 H, CH of
imidazole, J = 7.2 Hz); 7.13 (d, 1 H, CH of imidazole, J = 6.5
Hz); 7.22 (s, 1 H, CH—N); 7.33 (m, 2 H, CHpy); 7.42 (d, 2 H,
CHAr, J = 7.4 Hz); 7.62 (s, 1 H, CH of imidazole); 7.71 (t, 1 H,
CHpy, J = 7.5 Hz); 7.92 (d, 1 H, CHpy, J = 7.8 Hz); 8.06 (br.s,